Health
Statin drugs going generic
NEWS IN BRIEF — Posted May 15, 2006
A generic version of Pravachol, or pravastatin sodium, one of the top-selling cholesterol-lowering drugs, was approved by the Food and Drug Administration April 24. Pravachol lost patent protection April 20. Similar action is expected next month for another top seller, Zocor, or simvastatin, when that drug goes off-patent.
Pravastatin, manufactured in 10 mg, 20 mg and 40 mg, is one of several popular cholesterol-lowering medications. In 2005, Pravachol was the 22nd highest-selling brand-name drug in the United States, with sales totaling $1.3 billion. Insurers already are asking physicians to begin to switch patients from brand name to lower-price generic statins.
said Christie Ballantyne, MD, director of Baylor Medical College's Center for Cardiovascular Disease Prevention -- a not unusual occurrence with a change to any generic medication.
Physicians whose patients have been prescribed brand-name statins for many years are likely to find varying efficacy rates among the brands making it necessary to recheck liver functions and step up monitoring for muscle pain, at least initially, he noted.
It is likely that generic statins will save patients as well as the health care system a great deal of money, Dr. Ballantyne noted. An analysis by Consumers Union indicated that if Medicare Part D beneficiaries alone were prescribed effective generic statins instead of brand-name medications, the savings could mount to $8.2 billion next year.
Pricing information for the new generic pravastatin was expected shortly.
Note: This item originally appeared at http://www.ama-assn.org/amednews/2006/05/15/hlbf0515.htm.












